Adaptive Biotechnologies
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Adaptive Biotechnologies sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Adaptive Biotechnologies: 7 sponsored US clinical trials, 1 recruiting.
Adaptive Biotechnologies sponsors 7 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 4 completed. The most-studied condition in this pipeline is Lyme Disease, with 1 trials.
Upper-quartile sponsor footprint
Adaptive Biotechnologies sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
NCT05255354
ImmuneSense™ IBD Study
NCT05769829
ImmuneSense COVID-19 Variant Study
NCT05054088
The clonoSEQ® Watch Registry
NCT04545333
ImmuneSense™ COVID-19 Study
NCT04583982
ImmuneSense Lyme Study
NCT04422314
ImmuneRACE - Immune Response Action to COVID-19 Events
NCT04494893
Therapeutic Areas
What is open in the Adaptive Biotechnologies pipeline
1 recruiting of 7 indexed (14% open); 4 completed (57%).
Phase labels are sparse on this sponsor index, so phase mix is not charted here.
Top condition: Lyme Disease (1 trial), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Adaptive Biotechnologies: open-pipeline peers nationwide
Peers matched on 7 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Adaptive Biotechnologies sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 14% open enrollment (± trial volume)
- Academic and Community Cancer Research United · 14% recruiting · 42 trials
- AgelessRx · 14% recruiting · 7 trials
- Alaska Blind Child Discovery · 14% recruiting · 7 trials
- American College of Radiology · 14% recruiting · 14 trials
Related
What to do with this Adaptive Biotechnologies page
7 registered trials is a research-attention snapshot, not an endorsement of Adaptive Biotechnologies or any single study.
- 1 of Adaptive Biotechnologies's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Lyme Disease is the condition Adaptive Biotechnologies studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lyme Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Adaptive Biotechnologies pipeline card: 7 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.